Abstract:the mean reduction in RVSP across all three groups was 8.7% (SD ± 27.8%) (p = 0.00005). Patients with both moderate and severe pulmonary hypertension at baseline had significant mean RVSP reduction of 18% (SD ± 23.7%) (p = 0.0002) and 29.8% (SD ± 20.7%) (p = 0.001) respectively. No significant change was recorded in the mild group.Conclusion: TAVI resulted in statistically significant reductions in pulmonary hypertension in patients with moderate-to-severely elevated pulmonary pressures at baseline.
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.